CXCR4 mutation subtypes impact response and survival outcomes in patients with Waldenstrom macroglobulinaemia treated with ibrutinib

Jorge J. Castillo, Lian Xu,1 Joshua N. Gustine, Andrew Keezer, Kirsten Meid, Toni E. Dubeau, Xia Liu, Maria G. Demos, Amanda Kofides, Nicholas Tsakmaklis, Jiaji G. Chen, Manit Munshi, Maria L. Guerrera, Gloria G. Chan, Christopher J. Patterson, Guang Yang, Zachary R. Hunter and Steven P. Treon

CXCR4 mutation subtypes impact response and survival outcomes in patients with Waldenstrom macroglobulinaemia treated with ibrutinib

BJH - Received 23 March 2019; accepted for publication 21 May 2019 - First published online 3 July 2019 doi: 10.1111/bjh.16088